UK Researchers “Urgently” Developing Ebola Vaccine Based On Platform Used For Oxford/AstraZeneca COVID-19 Jab

Researchers at the Oxford Vaccine Group (OVG) are working “urgently” to development a vaccine for “Bundibugyo Ebolavirus” amid an outbreak in Africa.

“In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV,” a press release read.

The platform, which is a type of “viral-vector vaccine,” was used in the development of the Oxford/AstraZeneca COVID-19 jab.

A statement from the Oxford Vaccine Group and @UniofOxford on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC.

Read the full statement below or on our website: https://t.co/JRSzsEdBhz pic.twitter.com/P1k8HrKfIp

— Oxford Vaccine Group (@OxfordVacGroup) May 22, 2026

A closer look at the press release:

At the same time, we are working with our global